BPC-157: The Most Researched Peptide

Research · May 2026 · 7 min read · For informational purposes only

BPC-157 (Body Protection Compound-157) is a pentadecapeptide consisting of 15 amino acids. It is a partial sequence of the body protection compound derived from human gastric juice. First isolated and studied by Dr. Predrag Sikiric and colleagues at the University of Zagreb, BPC-157 has accumulated one of the most extensive bodies of preclinical research of any peptide compound.

Mechanisms of Action

Research on BPC-157 has identified several mechanisms through which it may exert its observed effects in preclinical models. Studies suggest it promotes angiogenesis — the formation of new blood vessels — through upregulation of VEGFR2 expression. This may explain the accelerated tissue healing observed in numerous animal models.

BPC-157 has also been shown in preclinical research to influence nitric oxide (NO) signalling, interact with the dopaminergic and serotonergic systems, and modulate growth hormone receptor expression. Its effects on the GABAergic system have also been investigated.

Research scope: As of 2024, BPC-157 has been studied in over 100 published preclinical studies covering tissue, muscle, tendon, ligament, bone, and organ models. It remains one of the most studied peptides in the research literature.

Administration Routes in Research

BPC-157 research has employed multiple administration routes, each with distinct characteristics:

Subcutaneous injection — most commonly used in rodent studies, allows systemic distribution
Multiple routes investigated in preclinical models
Intraperitoneal — common in rodent preclinical studies
Oral — investigated in some preclinical studies with variable results

Lyophilised powder stable at room temperature; store long-term at -20°C

Research-grade BPC-157

PureAura supplies pharmaceutical-grade BPC-157 for in vitro research. 99%+ purity, COA verified, EU delivery.

View BPC-157 →

Research Landscape

BPC-157 continues to attract significant research interest globally. Its stable gastric pentadecapeptide nature and the breadth of systems it appears to influence in preclinical models make it a compelling subject for ongoing investigation. Multiple research groups across Europe, North America and Asia are currently publishing findings on various aspects of BPC-157 biology.

Disclaimer: This article is for informational and educational purposes only. All PureAura products are sold strictly for in vitro laboratory research use. They are not medicines and are not approved for human administration. This content does not constitute medical advice.